Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AbbVie Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

NCT02065557
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Placebo
Biological
Lead sponsor
AbbVie
Industry
Eligibility
4 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 23, 2026, 1:11 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

NCT03725007
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

NCT07769502
View directory record Official record
Conditions
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers

NCT05895266
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-903, Midazolam
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

NCT03607422
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 23, 2026, 1:11 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Rituximab, Lenalidomide
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
31
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 2 Interventional

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00517790
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
ABT-869 .25 mg/kg, ABT-869 0.10 mg/kg
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
18
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 2 Interventional

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

NCT00872196
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
ABT-072
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 23, 2026, 1:11 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

NCT07059845
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Mirvetuximab Soravtansine, Bevacizumab, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
La Jolla, California • Solvang, California • Gainesville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

NCT07186595
View directory record Official record
Conditions
Mid Face Volume Deficit
Interventions
JUVÉDERM VOLUX XC, JUVÉDERM VOLUMA XC, JUVÉDERM VOLBELLA XC, JUVÉDERM VOLLURE XC, SKINVIVE by JUVÉDERM, JUVÉDERM ULTRA XC, JUVÉDERM ULTRA PLUS XC
Device
Lead sponsor
AbbVie
Industry
Eligibility
22 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Vista, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

NCT05686980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Anaheim, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 2 Interventional Results available

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction

NCT00935311
View directory record Official record
Conditions
Pain
Interventions
ABT-712 Extended-release, Hydrocodone/Acetaminophen Immediate-release, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Austin, Texas • San Marcos, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults

NCT06054425
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 23, 2026, 1:11 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Interventions
Dasatinib, Methotrexate, Prednisone, Rituximab, Venetoclax, Blinatumomab, Bone Marrow Aspiration and Biopsy, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

NCT01889186
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions
ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 23, 2026, 1:11 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions
Paricalcitol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Recruiting Phase 2 Interventional

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

NCT04905810
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Venetoclax
Drug
Lead sponsor
Brian Jonas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Clovis, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 23, 2026, 1:11 AM EDT
Completed No phase listed Observational

Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease

NCT02611713
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Boca Raton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 23, 2026, 1:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System

NCT07122583
View directory record Official record
Conditions
Non-Surgical Fat Reduction
Interventions
CoolSculpting Elite System
Device
Lead sponsor
AbbVie
Industry
Eligibility
22 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 1:11 AM EDT
Not listed Phase 4 Interventional

Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

NCT05503082
View directory record Official record
Conditions
Headache, Migraine
Interventions
Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy]
Drug
Lead sponsor
Chicago Headache Center & Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 23, 2026, 1:11 AM EDT
Withdrawn Phase 1 Interventional

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

NCT01969682
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABT-199, Rifampin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 23, 2026, 1:11 AM EDT